2009年2月
Clopidogrel Resistance in Japanese Patients Scheduled for Percutaneous Coronary Intervention
CIRCULATION JOURNAL
- 巻
- 73
- 号
- 2
- 開始ページ
- 336
- 終了ページ
- 342
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1253/circj.CJ-08-0559
- 出版者・発行元
- JAPANESE CIRCULATION SOC
Background Dual antiplatelet therapy with acetylsalicylic acid (ASA) and a P2Y(12) ADP-receptor blocker is standard for prevention of coronary stent thrombosis. Clopidogrel, a 2(nd)-generation P2Y12 blocker, has recently become available in Japan and this study aimed to evaluate its antiplatelet effects in Japanese patients.
Methods and Results Thirty Japanese patients scheduled for elective coronary stent implantation were enrolled. Under low-dose ASA therapy, 300 mg clopidogrel was loaded on the 1(st) day and a daily 75-mg dose was administered on the following days. Assessed by optical aggregometer, rapid inhibition occurred at 4 h, when the inhibition of platelet aggregation rate (IPA) was 16.4 +/- 12.8% using 5 mu mol/L ADP as the stimulus. The antiplatelet efficacy of clopidogrel was reasonably constant in each patient throughout the study period, although there was a broad inter-individual variation. At 48 h after clopidogrel loading, the ratios of responders (IPA 30%), hypo-responders (10%<= IPA<30%), and non-responders (IPA <10%) were 36%, 50%, and 14%, respectively.
Conclusions The antiplatelet effectiveness of clopidogrel appeared individual-specific with wide inter-individual variation. The rate of clopidogrel non-responders was 14% among the examined Japanese patients. (Circ J 2009; 73: 336-342)
Methods and Results Thirty Japanese patients scheduled for elective coronary stent implantation were enrolled. Under low-dose ASA therapy, 300 mg clopidogrel was loaded on the 1(st) day and a daily 75-mg dose was administered on the following days. Assessed by optical aggregometer, rapid inhibition occurred at 4 h, when the inhibition of platelet aggregation rate (IPA) was 16.4 +/- 12.8% using 5 mu mol/L ADP as the stimulus. The antiplatelet efficacy of clopidogrel was reasonably constant in each patient throughout the study period, although there was a broad inter-individual variation. At 48 h after clopidogrel loading, the ratios of responders (IPA 30%), hypo-responders (10%<= IPA<30%), and non-responders (IPA <10%) were 36%, 50%, and 14%, respectively.
Conclusions The antiplatelet effectiveness of clopidogrel appeared individual-specific with wide inter-individual variation. The rate of clopidogrel non-responders was 14% among the examined Japanese patients. (Circ J 2009; 73: 336-342)
- リンク情報
-
- DOI
- https://doi.org/10.1253/circj.CJ-08-0559
- J-GLOBAL
- https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902268258935637
- CiNii Articles
- http://ci.nii.ac.jp/naid/110007042175
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/19106460
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000262822300025&DestApp=WOS_CPL
- ID情報
-
- DOI : 10.1253/circj.CJ-08-0559
- ISSN : 1346-9843
- J-Global ID : 200902268258935637
- CiNii Articles ID : 110007042175
- PubMed ID : 19106460
- Web of Science ID : WOS:000262822300025